

Stroke Recovery Trial Fund Annual General Meeting Minutes


Date:	29 May 2019
Time:	5.30 pm
Place:	Tennis Centre Board Room Clive Berghoffer Recreation Centre, Baker Street, Toowoomba

Attendees:	Associate Professor Coralie Graham (SRTF Managing Director); Robyn Cavanagh (SRTF Director), Greg Stephan, Susan Ryan (SRTF Managing Director), Aletha Ward (SRTF Secretary/ Treasurer), Jennifer Le Saveant (Burns), Se Yen, Associate Professor Steve Ralph.
Apologies:	No apologies
Proxies:	Nil

Item	Description
1	Welcome and introductions
2	Apologies
3	<p>Chairperson's report</p> <p>Reported by Associate Professor Coralie Graham.</p> <ul style="list-style-type: none"> - Clinical trial phase 1 completed through the Griffith University School of Medical Science - Some more clinical trials now being undertaken. The \$1 million acquired through Minister Hunt was administered via the National Stroke Foundation via the National Health & Medical Research Council. The recipients have been announced but the research is yet to commence. - Provided community education to a number of community groups throughout the year. Most recently the Toowoomba Regional Council members and Mayor Cr Paul Antonio. Associate Professor Graham will be speaking to Lifeline in the coming weeks. - Fundraisers throughout the year included Bumper to Bumper in Townsville \$3,000; Stripes for Stroke \$1,000; Raffles throughout the year. Bendigo Bank Golf Day (Bi-annual) \$6,000; Stroll for Stroke (Sam Tee) who donated \$10,000. - Planning ahead – community information programs will continue.

	<p>UPCOMING EVENTS</p> <ul style="list-style-type: none"> - 30th August 2019 Stripes for Stroke fundraising evening in Toowoomba. <p>Proposed resolution: That the chairperson report be accepted. Moved: Aletha Ward Seconded: Robyn Cavanagh Passed</p>
4	<p>Treasurer's report/ Acceptance of financial statements. Reported by Aletha Ward. As per page 17 of the Annual report. Horizon Accounting audited the financial documents as per the reporting requirements of the charity. Proposed resolution: That the Treasurer's report and financial statements be accepted.</p> <p>Moved: Associate Professor Coralie Graham Seconded: Susan Ryan Passed</p>
5	<p>SRTF Annual report. Moved: Dr Coralie Graham moved that the annual report be accepted. Seconded: Robyn Cavanagh</p>
6	<p>Questions to Directors: Jennifer Burns asked if there were any organisations or philanthropists to be contacted. Associate Professor Graham will be in contact with some contacts that Mayor Paul Antonio has linked the charity with.</p>
7	<p>Election of SRTF Directors. Susan Ryan, Robyn Cavanagh and Associate Professor Coralie Graham indicated their willingness to continue in their current role as directors.</p>
8	<p>Guest speaker Associate Professor Stephen Ralph (Griffith university School of Medical Science) gave an update on the clinical trial.</p> <ul style="list-style-type: none"> - Phase 1 will be completed this weekend – last follow up will be occurring 2 weeks post treatment. - 26 participants have gone through Phase 1 of the trial. - Data entry is almost finished – once it is finished, the data will be unblinded and analysed. - Comparison between placebo and treated group will be analysed. There seemed to be a strong response in a number of participants particularly Group 5 (the last group of 5 participants). The research team have been doing Groups of 5 for a good distribution. Random assignment to placebo versus active for an even distribution. Ten participants or more in each group for comparison.

	<ul style="list-style-type: none"> - Will have a good indication in a couple of weeks time whether the trial has yielded statistically significant results. - If the results are not significant, another 20 will have to be recruited for Phase 2. - There is \$60, 000 of the money donated by the SRTF left in Griffith University account – so there are funds available if further participants need to be recruited. - There has been a cost reduction with a reduction in the cost of the drug, as the drug has come off patent (a reduction from \$800 to \$550 for a box of four vials of Etanercept. - All Clinical Trial participants are able to access the treatment post the clinical trial if they wish, at their own cost. This is approximately \$160 per drug and then extra for the Doctor’s time. Approximately \$400-\$500. - Some patients have severe neuropathic pain and no current medications work. Heavy sedative drugs are the only current treatment that affect their quality of life and it only dulls or numbs the pain. Post Clinical Trial: There has been a significant reduction in pain scores with one participant reporting a reduction in pain scores from 70-80, down to zero on the pain scale. - Trial went well with no significant side effects - If funding permitted, it would have been beneficial to have incorporated into the trial was brain scans to ascertain the immediate effects of the drug on the brain. - If further participants needed to be recruited for other Phases, Susan Ryan suggested targeted Facebook advertising and potential community announcements on radio. <p style="text-align: center;">Associate Professor Graham thanked Associate Professor Ralph and his team for their work with the clinical trial.</p>
9	<p>Other business arising:</p> <ul style="list-style-type: none"> - No further business arising -
10	<p>Close of Meeting: Dr Graham closed the meeting, thanking the current directors and members for their support.</p>
Minute taker:	Aletha Ward

Signed:	
Name:	Coralie Graham
Date:	30 May 2019